BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 33318036)

  • 1. SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies.
    Saqcena M; Leandro-Garcia LJ; Maag JLV; Tchekmedyian V; Krishnamoorthy GP; Tamarapu PP; Tiedje V; Reuter V; Knauf JA; de Stanchina E; Xu B; Liao XH; Refetoff S; Ghossein R; Chi P; Ho AL; Koche RP; Fagin JA
    Cancer Discov; 2021 May; 11(5):1158-1175. PubMed ID: 33318036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing Radioiodine Incorporation in
    Tchekmedyian V; Dunn L; Sherman E; Baxi SS; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Knauf JA; Pfister DG; Fagin JA; Ho AL
    Thyroid; 2022 Mar; 32(3):273-282. PubMed ID: 35045748
    [No Abstract]   [Full Text] [Related]  

  • 3. SWI/SNF chromatin remodeling and human malignancies.
    Masliah-Planchon J; Bièche I; Guinebretière JM; Bourdeaut F; Delattre O
    Annu Rev Pathol; 2015; 10():145-71. PubMed ID: 25387058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2.
    Kim KH; Kim W; Howard TP; Vazquez F; Tsherniak A; Wu JN; Wang W; Haswell JR; Walensky LD; Hahn WC; Orkin SH; Roberts CW
    Nat Med; 2015 Dec; 21(12):1491-6. PubMed ID: 26552009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BAFfling pathologies: Alterations of BAF complexes in cancer.
    Arnaud O; Le Loarer F; Tirode F
    Cancer Lett; 2018 Apr; 419():266-279. PubMed ID: 29374542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth.
    Kim KH; Roberts CW
    Cancer Genet; 2014 Sep; 207(9):365-72. PubMed ID: 24853101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SWI/SNF Complex Mutations in Gynecologic Cancers: Molecular Mechanisms and Models.
    Wang Y; Hoang L; Ji JX; Huntsman DG
    Annu Rev Pathol; 2020 Jan; 15():467-492. PubMed ID: 31977292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The spectrum of SWI/SNF mutations, ubiquitous in human cancers.
    Shain AH; Pollack JR
    PLoS One; 2013; 8(1):e55119. PubMed ID: 23355908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
    Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
    Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
    [No Abstract]   [Full Text] [Related]  

  • 10. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
    Cheng L; Jin Y; Liu M; Ruan M; Chen L
    Oncotarget; 2017 Mar; 8(12):19843-19854. PubMed ID: 28423638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remodeling the cancer epigenome: mutations in the SWI/SNF complex offer new therapeutic opportunities.
    Orlando KA; Nguyen V; Raab JR; Walhart T; Weissman BE
    Expert Rev Anticancer Ther; 2019 May; 19(5):375-391. PubMed ID: 30986130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
    Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
    Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SWI/SNF complex-deficient soft tissue neoplasms: An update.
    Schaefer IM; Hornick JL
    Semin Diagn Pathol; 2021 May; 38(3):222-231. PubMed ID: 32646614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SWI/SNF Alterations in Squamous Bladder Cancers.
    Achenbach F; Rose M; Ortiz-Brüchle N; Seillier L; Knüchel R; Weyerer V; Hartmann A; Morsch R; Maurer A; Ecke TH; Garczyk S; Gaisa NT
    Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33227989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.
    Chakravarty D; Santos E; Ryder M; Knauf JA; Liao XH; West BL; Bollag G; Kolesnick R; Thin TH; Rosen N; Zanzonico P; Larson SM; Refetoff S; Ghossein R; Fagin JA
    J Clin Invest; 2011 Dec; 121(12):4700-11. PubMed ID: 22105174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SWI/SNF deficient central nervous system neoplasms.
    Cai C
    Semin Diagn Pathol; 2021 May; 38(3):167-174. PubMed ID: 33762087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus.
    Kia SK; Gorski MM; Giannakopoulos S; Verrijzer CP
    Mol Cell Biol; 2008 May; 28(10):3457-64. PubMed ID: 18332116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.
    Agaimy A; Amin MB; Gill AJ; Popp B; Reis A; Berney DM; Magi-Galluzzi C; Sibony M; Smith SC; Suster S; Trpkov K; Hes O; Hartmann A
    Hum Pathol; 2018 Jul; 77():139-146. PubMed ID: 29689242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer--mechanisms and potential therapeutic insights.
    Wang X; Haswell JR; Roberts CW
    Clin Cancer Res; 2014 Jan; 20(1):21-7. PubMed ID: 24122795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the SWI/SNF chromatin remodeling complex in pancreatic ductal adenocarcinoma.
    Tsuda M; Fukuda A; Kawai M; Araki O; Seno H
    Cancer Sci; 2021 Feb; 112(2):490-497. PubMed ID: 33301642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.